



Transgene Announces Financial Calendar for 2022

Strasbourg, January 6th, 2022 - 05:45 pm CET

TRANSGENE (Paris: TNG) today announced its financial reporting dates for 2022:

March 16, 2022: 2021 Fiscal Year Results

May 10, 2022: First Quarter 2022 Financial Results

May 25, 2022: Annual Shareholders' Meeting

September 14, 2022: First Half 2022 Financial Results

November 7, 2022: Third Quarter 2022 Financial Results

Contacts

Transgene:
Jean-Philippe Del
Chief Financial Officer
+33 (0)3 88 27 91 00
investorrelations@transgene.fr

Media Transgene: MEDISTRAVA Consulting David Dible/Sylvie Berrebi +44 (0)7714 306525 transgene@medistrava.com

About Transgene

Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing cancer cells.

The Company's clinical-stage programs consist of two therapeutic vaccines (TG4001 for the treatment of HPV-positive cancers, and TG4050, the first individualized therapeutic vaccine based on the $myvac^{*}$ platform) as well as two oncolytic viruses (TG6002 for the treatment of solid tumors, and BT-001, the first oncolytic virus based on the Invir.IOTM platform).

With Transgene's *myvac*® platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The *myvac*® approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC.

With its proprietary platform Invir.IO[™], Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses. Transgene has an ongoing Invir.IO[™] collaboration with AstraZeneca. Additional information about Transgene is available at: www.transgene.fr

Follow us on Twitter: @TransgeneSA

